A randomised, double-blind, placebo-controlled trial to evaluate the efficacy of orally administered Triiodothyronine (T3) for 24 weeks in patients with heart failure with reduced ejection (HFrEF) - TheT3-HF Trial
National Institute for Health and Care Research
· United Kingdom · £260.72M GBP
We use cookies to keep your session secure, remember your preferences, and analyse site traffic with Google Analytics.
By continuing to use GrantFunds you agree to our
Privacy Policy
and
Terms of Use.